MoonLake Immunotherapeutics

What they do

MoonLake is a single-asset company exclusively licensed from Merck Healthcare KGaA (MHKDG) to develop and commercialize SLK (sonelokimab), a novel tri-specific Nanobody targeting IL-17A and IL-17F. The company is running Phase 3 trials in hidradenitis suppurativa (HS) and psoriatic arthritis (PsA), with earlier programs in axial spondyloarthritis and palmoplantar pustulosis. No product is approved for commercial sale; all operations are R&D-focused. SLK is designed with a small size and albumin-binding domain to enhance tissue penetration in skin and joints.

Revenue drivers

• Sonelokimab (SLK) – HS program — Phase 3 VELA-1 and VELA-2 trials in hidradenitis suppurativa; VELA-1 met primary endpoint (HiSCR75 34% at week 16, delta 17% vs placebo, p<0.001), VELA-2 missed statistical significance (delta 9%, p=0.053). No revenue yet.
• Sonelokimab (SLK) – PsA program — Phase 3 IZAR-1 trial in biologic-naive psoriatic arthritis met all clinical endpoints at week 16 for 60 mg (ACR50 42.1%, ACR20 66.5%, MDA 41.2%, PASI90 61%). IZAR-2 in TNF-refractory patients expected to complete enrollment Q3 2026. No revenue yet.
• Other IL-17 driven indications — Pipeline includes axial spondyloarthritis, palmoplantar pustulosis, and psoriasis; these are earlier-stage or planned studies. No revenue contribution expected near-term.

Recent performance

For the year ended December 31, 2025, MoonLake reported a net loss of $227.3 million and diluted EPS of -$3.53, with operating cash flow of -$196.0 million. Losses have widened from -$118.9 million in 2024 and -$36.0 million in 2023. As of June 30, 2026, the company held $537.0 million in cash, equivalents, and short-term marketable securities (per the August 2026 release), with total assets of $573.9 million and total liabilities of $145.8 million. Second-quarter 2026 results were released on August 10, 2026, alongside the IZAR-1 topline success. The company has not generated any product revenue.

Strategy

Management is focused on advancing SLK through Phase 3 development in HS and PsA, with regulatory filings and commercialization as the next milestones. The company relies on a licensing agreement with MHKDG and a debt facility with Hercules Capital (up to $400 million non-dilutive). It aims to leverage SLK's differentiated mechanism to address high unmet need across multiple IL-17 driven inflammatory diseases. Key priorities include completing the IZAR-2 trial, reporting full IZAR-1 data at Week 52 (expected H1 2027), and preparing for regulatory interactions following the HS Phase 3 results.

Risks

• Single-asset dependence — MoonLake is substantially dependent on the success of SLK; failure in any trial would materially harm the business.
• Licensing termination risk — The company's rights to SLK come from MHKDG and RCT; a breach or failure to meet diligence obligations could result in loss of development and commercialization rights.
• No regulatory approvals or revenue — The company has no approved products and no revenue; it may never achieve profitability.
• Capital needs and dilution — The company expects significant losses for the foreseeable future and will need substantial additional capital to fund operations; existing cash runway only extends to mid-2028.

Outlook

Management expects the IZAR-1 trial to continue blinded until Week 52, with full readout in H1 2027, and IZAR-2 enrollment to complete in Q3 2026. The company guides to a cash runway through mid-2028, with up to $400 million in non-dilutive funds available via the Hercules Capital debt facility. Regulatory submissions for HS are anticipated following Phase 3 data, though no specific timeline was provided.